Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a …
B Ljungberg, P Sundqvist, P Lindblad… - … journal of urology, 2020 - Taylor & Francis
Background Recently, the CARMENA and SURTIME studies, suggested that upfront
cytoreductive nephrectomy (CN) should be abandoned for patients with intermediate and …
cytoreductive nephrectomy (CN) should be abandoned for patients with intermediate and …
Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma
B Bhindi, EJ Abel, L Albiges, K Bensalah, SA Boorjian… - European urology, 2019 - Elsevier
Context The role of cytoreductive nephrectomy (CN) in the management of metastatic renal
cell carcinoma (mRCC) in the targeted therapy (TT) era is controversial. Objective To assess …
cell carcinoma (mRCC) in the targeted therapy (TT) era is controversial. Objective To assess …
Deferred cytoreductive nephrectomy in the management of metastatic renal cell carcinoma: A systematic review and meta-analysis
Deferred cytoreductive nephrectomy (dCN) after upfront systemic therapy has been utilized
in the management of select patients with metastatic renal cell carcinoma (mRCC). Herein …
in the management of select patients with metastatic renal cell carcinoma (mRCC). Herein …
[HTML][HTML] Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma
C Van Praet, C Slots, N Vasdev, S Rottey… - Turkish journal of …, 2021 - ncbi.nlm.nih.gov
Historically, immediate cytoreductive nephrectomy (CN) was considered the standard of
care in patients with metastatic renal cell carcinoma (mRCC) who were fit enough to …
care in patients with metastatic renal cell carcinoma (mRCC) who were fit enough to …
Long-term survival outcomes of cytoreductive nephrectomy combined with targeted therapy for metastatic renal cell carcinoma: a systematic review and individual …
Simple Summary Cytoreductive nephrectomy (CN) refers to the removal of the primary renal
tumor in the setting of metastatic renal cell carcinoma. In the past, the combination of CN …
tumor in the setting of metastatic renal cell carcinoma. In the past, the combination of CN …
Prognostic value of cytoreductive nephrectomy combined with targeted therapy for metastatic renal cell carcinoma: a meta-analysis
X Hong, F Li, K Tang, S Pang, G Lin, S Li, J Bao… - … Urology and Nephrology, 2016 - Springer
Purpose The role of cytoreductive nephrectomy (CN) has been controversial with the advent
of targeted therapy. Our study was to identify the prognostic value of CN combined with …
of targeted therapy. Our study was to identify the prognostic value of CN combined with …
Outcomes of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma: real world data from canadian centers
A Dragomir, S Nazha, S Tanguay, RH Breau… - European urology …, 2022 - Elsevier
Background Treatment options for metastatic renal cell carcinoma (mRCC) include
cytoreductive nephrectomy (CN) and systemic therapy (ST). Results from the CARMENA …
cytoreductive nephrectomy (CN) and systemic therapy (ST). Results from the CARMENA …
Cytoreductive Nephrectomy in Select Primary Metastatic Renal Cell Carcinoma Patients: A Comprehensive Nationwide Outcome Analysis
N Azawi, L Geertsen, N Nadler, KSS Mosholt… - Cancers, 2024 - mdpi.com
Simple Summary This stduy focuses on a specific surgery for advanced kidney cancer that
has spread, known as cytoreductive nephrectomy. The study examined the health results of …
has spread, known as cytoreductive nephrectomy. The study examined the health results of …
The role of cytoreductive nephrectomy in metastatic renal cell carcinoma: a real-world multi-institutional analysis
P Ghatalia, EA Handorf, DM Geynisman… - The Journal of …, 2022 - auajournals.org
Purpose: The role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma
(mRCC) was challenged by the results of the CARMENA trial. Here we evaluate the role of …
(mRCC) was challenged by the results of the CARMENA trial. Here we evaluate the role of …
[HTML][HTML] Upfront cytoreductive nephrectomy vs. upfront systemic therapy in metastatic kidney cancer
A Kapoor, ECL Wong, W Fang… - Canadian Urological …, 2019 - ncbi.nlm.nih.gov
Methods We performed a retrospective analysis at our institution of consecutive patients with
mRCC who underwent CN and received TKIs between 2009 and 2016. We included any …
mRCC who underwent CN and received TKIs between 2009 and 2016. We included any …